Mayne Pharma shares surge on $407 mln takeover offer from Gedeon Richter
Australian pharmaceutical firm Mayne Pharma (ASX:MYX) announced on Tuesday that it had reached an agreement to be acquired by Hungarian company Gedeon Richter PLC (BU:GDRB) for A$604 million ($407 million), causing its shares to experience a significant increase. As part of the agreed terms, Richter will purchase all of Mayne Pharma's shares for A$6.40 each in cash, which is a 99.4% premium over the company's closing share price on November 16.
Mayne Pharmaceuticals' shares on the Sydney market surged by up to 86.3% to A$5.98 by 00:51 GMT, reaching their highest level since November 2025. The company's board recommended shareholders to approve the deal, assuming there is no better offer and provided that an independent expert confirms the transaction benefits shareholders.
The acquisition is fully funded by Richter's internal cash resources and is contingent on regulatory approvals, shareholder and court approval, as well as the completion of Mayne Pharma's earlier planned sale of its international business to Evaris Pharma.
The shareholder vote is anticipated in late January 2027, with the transaction expected to be finalized in March. Richter believes that the acquisition will bolster its presence in the United States, particularly in the women's health and other therapeutic segments.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.